Pharma News

Patients with a particular kind of cancer and a particular kind of mutation received a new therapy called dostarlimab and had results not seen in a cancer trial before. ...

Praxis Precision Medicines’ investigational GABA type A receptor drug PRAX-114 failed a phase 2/3 clinical trial that was evaluating the drug’s efficacy and safety as monotherapy for patients w...

New research has found that Pseudomonas bacterium develops resistance much faster than usual to a common ‘last-resort’ antibiotic.

Researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) have found that oral administration of rapamycin to an Alzheimer’s disease mouse model causes...

For the first time in half a decade, the U.S. Food and Drug Administration’s Cell, Tissue and Gene Therapies Advisory Committee will convene to address two therapies developed by bluebird bio in ...

The UK’s Medicines and Healthcare products Regulatory Agency has approved VBI Vaccines’ PreHevbri three-antigen vaccine for immunization of adults against infection by all known subtypes of th...

A team of researchers from the Brown Cancer Center, the University of Louisville, Peak Neuromonitoring Associates, the University of Texas and the University of Louisville has found that a metabol...

Alzheimer’s patients given the experimental tau-targeting therapy HMTM in a Phase 3 clinical trial experienced a substantially slower decline in cognitive and functional measures than would be e...

The FDA announced that it has withdrawn approval for umbralisib (Ukoniq, TG Therapeutics), based on an updated analysis of the phase 3 UNITY-CLL clinical trial, which continues to show “a possibl...

Pfizer’s Paxlovid (nirmatrelvir, ritonavir) significantly reduced the risk of severe COVID-19 infection or mortality, Israeli researchers reported.

GSK shared exciting news Monday morning, announcing that the company’s vaccine for protection against measles, mumps and rubella (MMR) has been approved by the U.S. Food and Drug Administration.&...

Bristol Myers Squibb announced Friday that it is acquiring San Diego-based Turning Point Therapeutics in a deal totaling about $4.1 billion.